In such as LDH and IPI23.More importantly, we

In the
present work, we  explored the expression
of  miR-155 in plasma samples of DLBCL
patients  and  healthy 
individuals  by  qRT-PCR 
for  the  first 
time. Based on the relative expression analysis, it was  explored that the association of miR-155 with prognosis
and clinical characteristics of patients with DLBCL. Results showed that the plasma
level of miR-155 was over-expression in DLBCL cases compared with that in
healthy individuals (P<0.05). Theses finding agree with previous studies that  the  expression of miR-155 was increased in  DLBCL cells and was used as an independent prognostic indicator of survival in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) treated DLBCL patients 25 . Kluiver et al demonstrated in DLBCL cases, expression of plasma miR-155 was significantly higher than healthy individuals21. Zhong et al. reported that miR-155 expression was significantly higher in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma compared with normal controls23  . An additional report showed that a correlation between miRN-155 and NF-kB expression in DLBCL patients and cell lines 26Furthermore, it was also showed that the relative expression level of miR-155 was closely associated with B symptoms, LDH level and advanced stage of disease (stage III/IV).  However, the level of miR-155 expression had not correlation with age, sex and IPI score. Whereas, miR-155 levels was not associated with clinical prognostic factors, such as LDH and IPI23.More importantly, we showed that miR-155 expression was significantly correlated with overall survival by Kaplan-Meier analysis and log-rank test. The cases with elevated miR-155 level had shorter overall survival compared to those with low levels of miR-155 expression. Theses finding is in line with previous report that the DLBCL patients with a high miR-155 expression level had a significantly poorer OS27. Remarkably, Roehle et al, revealed that miR-155 level was not as a prognostic marker for survival, although this miRNA has been described to be exclusively overexpressed in ABC-DLBCL22. These finding showed that an up-regulated expression level of miR-155 correlates with poor survival prognosis.  In conclusion, the findings propose that miR-155 has the potential to be as a robust biomarker and a prognostic target for better classify of DLBCL patients in future. Since a few studies have accomplished on the investigating the relationship between miR-155 expression and the DLBCL prognosis, hence more studies would be required to elucidate the exact biological mechanisms to validate our conclusions

Written by